Literature DB >> 1712114

Cerebrospinal fluid levels of monoamine metabolites in panic disorder.

E Eriksson1, P Westberg, C Alling, K Thuresson, K Modigh.   

Abstract

The cerebrospinal fluid (CSF) levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5HIAA), the noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), and the dopamine metabolite homovanillic acid (HVA) did not differ significantly in a group of patients with panic disorder (n = 17) as compared to age- and sex-matched normal controls (n = 17). While CSF concentrations of HVA and 5HIAA were significantly correlated in both patients and controls, CSF MHPG levels were significantly correlated with the concentrations of CSF 5HIAA and HVA only in patients. In a small number of subjects (n = 5), successful reduction of anxiety attacks by administration of clomipramine or imipramine (50-150 mg/day) for at least 2 months was associated with a significant decrease in CSF concentrations of 5HIAA and MHPG, but not HVA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712114     DOI: 10.1016/0165-1781(91)90023-i

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

Review 1.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

2.  NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo.

Authors:  Akihiro Takano; Sangram Nag; Balázs Gulyás; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2011-02-19       Impact factor: 4.530

Review 3.  Panic disorder. Pathophysiology and drug treatment.

Authors:  M R Johnson; R B Lydiard; J C Ballenger
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

4.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.